Phaseline

Companies › MBX Biosciences

MBX Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 1 Phase 1, 1 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Canvuparatide
PTH analog (parathyroid hormone analog)
PTHR1Phase 3HypoparathyroidismJan 2028
MBX 2109
PTH receptor agonist (presumed)
–Phase 2HypoparathyroidismMay 2028
MBX 4291–Phase 1Obesity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07142707MBX 4291Phase 1ObesityMetabolic and endocrineOct 2026
NCT07699471CanvuparatidePhase 3HypoparathyroidismMetabolic and endocrineJan 2028
NCT06531941MBX 2109Phase 2HypoparathyroidismMetabolic and endocrineMay 2028

From the company's SEC filings

Cash and short-term investments of $482m on 2026-09-30; operating cash outflow about $104m a year; runway about 55 months at that burn, to May 2031; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

PTHR1 (1)

Companies with the same targets

–

Companies built like this

Amylyx Pharmaceuticals Rhythm Pharmaceuticals Vogenx Calcilytix Therapeutics, Inc., a BridgeBio company vTv Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.